| Dr. Michael J Hampton | |
|
1604 Professional Cir, Yukon, OK 73099-6314 | |
| (405) 354-3624 | |
| (405) 350-7512 |
| Full Name | Dr. Michael J Hampton |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 1604 Professional Cir, Yukon, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831318633 | NPI | - | NPPES |
| 731276615001 | Other | OK | BLUE CROSS BLUE SHIELD |
| 100762440A | Medicaid | OK | |
| 47250 | Other | UT | SPECTERA |
| 0182270001 | Other | SC | PALMETTO GBA |
| OK01109 | Other | PA | VISION BENEFITS OF AMERIC |
| 1031427 | Other | AETNA HEALTH CARE | |
| CE813 | Other | OK | BLUELINCS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1109 (Oklahoma) | Primary |
| Provider Name | Jason M Myers |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1427319508 PECOS PAC ID: 1456509660 Enrollment ID: I20120913000158 |
News Archive
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Viruses are tiny bundles of DNA or RNA which have the ability to infect host cells, hijack the machinery of the host cell and then replicate. Once the host cell's resources are exhausted, the viral particles are released to infect other cells. In this way, the viruses ensure their survival, often at the expense of the host.
Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes about an approach known as "three share" which helps expand health coverage by spreading health insurance premium costs among the community, the employer and the worker.
Recently, researchers from the UK and Sweden used highly sensitive multiplexed immunohistochemistry to study the brain tissue of COVID-19 patients and controls to analyze ACE2 expression in brain pericytes of patients with neurological symptoms. They also used spatial immunophenotyping to assess inflammation in brain tissue of COVID-19 patients.
Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).
› Verified 1 days ago
| Provider Name | Tazia Ann Cook |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1750804134 PECOS PAC ID: 4486928306 Enrollment ID: I20170915001831 |
News Archive
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Viruses are tiny bundles of DNA or RNA which have the ability to infect host cells, hijack the machinery of the host cell and then replicate. Once the host cell's resources are exhausted, the viral particles are released to infect other cells. In this way, the viruses ensure their survival, often at the expense of the host.
Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes about an approach known as "three share" which helps expand health coverage by spreading health insurance premium costs among the community, the employer and the worker.
Recently, researchers from the UK and Sweden used highly sensitive multiplexed immunohistochemistry to study the brain tissue of COVID-19 patients and controls to analyze ACE2 expression in brain pericytes of patients with neurological symptoms. They also used spatial immunophenotyping to assess inflammation in brain tissue of COVID-19 patients.
Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr. Michael J Hampton 1604 Professional Cir, Yukon, OK 73099-6314 Ph: (405) 354-3624 | Dr. Michael J Hampton 1604 Professional Cir, Yukon, OK 73099-6314 Ph: (405) 354-3624 |
News Archive
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Viruses are tiny bundles of DNA or RNA which have the ability to infect host cells, hijack the machinery of the host cell and then replicate. Once the host cell's resources are exhausted, the viral particles are released to infect other cells. In this way, the viruses ensure their survival, often at the expense of the host.
Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes about an approach known as "three share" which helps expand health coverage by spreading health insurance premium costs among the community, the employer and the worker.
Recently, researchers from the UK and Sweden used highly sensitive multiplexed immunohistochemistry to study the brain tissue of COVID-19 patients and controls to analyze ACE2 expression in brain pericytes of patients with neurological symptoms. They also used spatial immunophenotyping to assess inflammation in brain tissue of COVID-19 patients.
Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).
› Verified 1 days ago
Oklahoma Eye Specialist Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2001 Wheatfield Ave, Yukon, OK 73099 Phone: 405-308-3430 | |
Michael Joseph Hampton, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1604 Professional Cir, Yukon, OK 73099 Phone: 405-354-3624 Fax: 405-350-7512 | |
Total Optical Llc Optometrist Medicare: Medicare Enrolled Practice Location: 4400 Grant Blvd, Suite 106, Yukon, OK 73099 Phone: 405-603-4744 | |
Legacy Eye Care Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 1207 Cornwell Dr, Yukon, OK 73099 Phone: 405-354-3384 | |
Dr. John Mace, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: Ultimate Vision, 334 S. Mustang Rd, Yukon, OK 73099 Phone: 405-324-0001 Fax: 405-324-0015 | |
Dr. Valerie Ridgena Hatley, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 621 W Main St, Yukon, OK 73099 Phone: 405-354-2788 | |
Dr. David Charles Brewer, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1207 S Cornwell Dr, Yukon, OK 73099 Phone: 405-354-3384 Fax: 405-354-0703 |